Child DevelopmentNCT06917625
Follow up of Long Term Neurodevelopmental Impact of the Type of Feeding During the First Year of Life at 10 Years Old
An observational study of Child Development, run by Corporación de Apoyo de la Investigación Científica en Nutrición at 1 site in Chile.
Trial summary
The Chilean infant Nutrition Trial was a prospective, randomized, double-blind, controlled study conducted in Santiago, Chile, between 2016 and The study aimed to evaluate growth and body composition changes between birth and two years of age in a large sample of children who were randomized to receive either infant… Read more about this study
- Who is it for?
- Ages 10 to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Child Development
- What is being tested?
- Imaging
- How many people
- 5 participants
- Where
- 1 siteChile
- Study dates
- 11 Mar 2025to Jan 2026
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: Study population was selected from the neighborhoods close to the installation of research institute. The area corresponds to the southeast of Santiago, Chile
Inclusion Criteria: Healthy, have been studied at 2 and 6 years old in the laboratory -
Exclusion Criteria: To have a diagnosis of a neurological disease.
-
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Long Term Neurodevelopmental Impact of the Type of Feeding During the First Year of Life Neuroimaging and Electrophysiology Follow up Study
The Chilean infant Nutrition Trial was a prospective, randomized, double-blind, controlled study conducted in Santiago, Chile, between 2016 and The study aimed to evaluate growth and body composition changes between birth and two years of age in a large sample of children who were randomized to receive either infant formula with or without added MFGM (milk fat globule membrane) through 12 months of age or received human milk as part of the reference group. In a subsample of 160 children, neurodevelopmental were assessed at 6 months and 24 months.
Read the detailed description
To test our hypothesis, this study proposes to investigate our conceptual model's direct and indirect associations using a combination of low-field MRI, electrophysiology, and psychometric assessments of executive functioning and general cognitive development, expecting to re-enroll approx 100 participants. These children will undergo ERPs, low-field MRI and neurocognitive testing to evaluate brain structure, function, and cognitive development.
The Go/No-Go task assesses inhibitory control, one of the most important executive function. Its development has been studied electrophysiologically using event-related potentials (ERPs), in tasks that require active inhibition when there is a previously learned or prepotent response. The main relevant ERP components are the N2 and P300. The N2, an early negative deflection, has been interpreted to reflect attention, the P300, a later positive wave, is thought to reflect resource allocation. The P300 is typically greater in the inhibitory than in the prepotent response components of tasks such as the Go/No-Go task. Behavioral responses such as accuracy and reaction time have also been studied as measures of development (2). Using the collected data, inhibitory control, as one of the earliest executive functions to begin developing, will be studied.
The data acquired with the Low-field MRI quantify and compare brain structure and myelination patterns (derived from MRI) across the feeding groups in specific white matter pathways and brain regions involved in executive function (EF) and throughout the brain generally. MRI comparisons and comparisons will be complemented by comparisons of ERP measures collected during an inhibition task, which assesses functional development and processing speed.In addition to these group-wise comparisons,it will be explored the direct and indirect infant feeding -> brain structure and function -> executive function and cognitive performance associations using a series of ANCOVA and general linear modeling methods.
- PRIMARY OBJECTIVE AND OUTCOME MEASUREMENTS:
The primary objective of this study is to determine whether additional intake of bMFGM during infancy (0-12 months of age) improves brain structure, function, and cognitive performance (specifically EF) at early school age (8-10 years of age).
The following measures will be collected, and EF domains assessed and comparisons made.
Brain Structure and Myelin Imaging. Low-Field MRI will be used to assess general brain growth and morphometry (total brain volume, whole-brain white and gray matter volume, and cortical and sub-cortical structure volumes) as well as myelination using myelin-sensitive MRI. Differences across all of these measures between the infant feeding groups (standard formula, added bMFGM, and breastfeeding reference) will be part of exploratory analysis. To examine specific hypothesized brain regions involved in EF, including prefrontal cortex, hippocampus, amygdala, thalamus, motor and somatosensory cortices, and auditory cortex will be studied. Connecting white matter regions, including corpus callosum, cingulum, superior longitudinal fasciculus, and anterior thalamic radiations will be compared as they are an indirect index of myelination grade.
Mean myelin measures will be calculated for each white matter pathway and compared across the three feeding groups using an ANCOVA and post hoc Tukey test to identify significant differences.
ERPs and Electrophysiology. ERPs will be recorded from 128 scalp sites using a recording system with a geodesic sensor net (Electric Geodesic, Inc., Eugene, Oregon). The vertex was used as the on-line reference electrode. The signal was sampled at 1000 Hz and bandpass filtered at 0.1 to 100 Hz. After recording, stimulus triggers were exported and analyzed using signal processing software (BESA Research 6.1 BESA® ,Germany). Signals were re-referenced off-line to an average (whole head) reference and bandpass filtered (0.1 to 10 Hz). The continuous EEG was segmented into epochs according to the three stimulus types: block 1 Go trials, block 2 Go trials, and block 2 No-Go trials with the segment length being the same as each onset-to-onset interval. Noisy segments of data with excessive electromyographic signal (EMG) were rejected by visual inspection, and noisy channels were identified and rejected using a 2.5% probability threshold and visual inspection. Each trial will last 1000ms and consist of 100ms of pre-stimulus presentation, 500ms of stimulus presentation, and 1000ms of stimulus recording. The intertrial interval was 500 to 700ms. For the ERP analysis, window time was selected to establish where to determine the components of interest, which were identified relative to the number of major positive and negative peaks following stimulus onset. All time window values were relative to stimulus onset, and the peak amplitudes were calculated relative to the baseline amplitude. Statistical analyses were conducted with SPSS software version 25.0.1 (SPSS Inc., Chicago, IL, USA). Behavioral measures were reaction time and accuracy. Electrophysiological measures were peak amplitude and latency for N2 and amplitude for P300. Covariates that indicated group differences were considered in subsequent analyses as potential confounders.
Age-appropriate EF Psychometric Assessments will be used to evaluate executive functions. The EFECO assessment that are the abbreviation Evaluation of executive function throughout conductual observation. The questionnaire will be filled by the adult in charge of the participant.
- Conditions
- Child Development
- Being tested
- Imaging
- Keywords
- early nutrition, brain development
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ImagingDiagnostic test
Also called Event related potential test
The participants will be assessed with a brain MRI and will performed a neurophysiological test to evaluate executive functions
| Study group | Role | What they receive |
|---|---|---|
| FM EM | During the first year of life the participants received
1. regular formula milk
2. enriched with Milk Fat Membrane Globule formula Receives: Diagnostic Test: Imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine if intake of bMFGM during the first year improves brain structure at 9 ys.
Low-Field MRI will be used to assess general brain growth and morphometry (total brain volume, whole-brain white and gray matter volume, and cortical and sub-cortical structure volumes) as well as myelination using myelin-sensitive MRI. For specific analysis will examine brain regions involved in EF, including prefrontal cortex, hippocampus, amygdala, thalamus, motor and somatosensory cortices, and auditory cortex ; and connecting white matter regions, including corpus callosum, cingulum, superior longitudinal fasciculus, and anterior thalamic radiations .The results will be expressed by mean volumetric measures calculate from the MRI data using validated FreeSurfer software and compared across the groups using an ANCOVA, controlling for variables of interest. Mean myelin measures will be calculated for each white matter pathway and to identify significant differences (express by grade of myelination)
Measured: MRI assessment will be performed at 9 years old in a session of 45 minutes
To determine if intake of bMFGM during the first year improves EF measures by ERPs at 9ys.
. To assess EF the Go No Go task will be performed with ERPs. The participant will ask to press a button when any letter appears (Go stimulus) except when the letter will be X (No Go stimulus). There will be 2 blocks: Block 1(40 trials) of Go stimulus and Block 2 (200 trials) of randomized Go and No Go stimuli. Neurophysiological responses will be recorded from 128 scalp sites using a recording system with a geodesic sensor net .For the ERP analysis, the major positive and negative peaks following stimulus onset will be identified. Statistical analyses were conducted with SPSS software version 25.0.1. Behavioral measures will be reaction time (ms) and accuracy (%). Electrophysiological results will be the peak amplitude (mµ) and latency (ms) for the waves N2 and P300.
Measured: ERPs assessment will be performed at 9 years old in a a second session of 90 minutes .
To determine if intake of bMFGM during the first year improves EF measures by questionnaire EFECO.
The questionnaire EFECO evaluates executive functions throughout conductual observation.
The scale has 67 questions which measure seven different executive functions: cognitive flexibility, emotional control, planification capacity, organization, initiative and working memory. The quantification of each item goes from 0 to 3 according with one of these responses: Never, sometime, frequently, and very frequently. The higher score corresponds to a better EF. The questionnaire will be filled by the adult accompanying the participant during the ERP measurement and confirm that lives with the participant.
Measured: EFECO will be answered by the adult that ERPs assessment will be performed at 9 years old in a a second session of 90 minutes .
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2025
- Study start11 Mar 2025
- Primary completionJan 2026 (estimated)
- Study completionJan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Child DevelopmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Corporación de Apoyo de la Investigación Científica en Nutrición
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cecilia Algarin, Corporación de Apoyo de la Investigación Científica en Nutrición
- Investigators
- Patricio Peirano, MD, Study director, University of Chile
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06917625
- Sponsor's protocol ID
- MJCINUT8736
- Status last verified
- Apr 2025
- First submitted
- 24 Mar 2025
- Last updated
- 8 Apr 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data published in an article could be share with other researchers
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long Term Neurodevelopmental Impact of the Type of Feeding During the First Year of Life Neuroimaging and Electrophysiology Follow up Study
- ClinicalTrials.gov ID
- NCT06917625
- Acronym / sponsor ID
- MJCINUT8736
- Conditions
- Child Development
- Keywords
- early nutrition, brain development
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Corporación de Apoyo de la Investigación Científica en NutriciónUniversity, hospital or other
- Study start
- 11 Mar 2025 (actual)
- Primary completion
- Jan 2026 (estimated)
- Study completion
- Jan 2026 (estimated)
- First posted
- 8 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Chilean infant Nutrition Trial was a prospective, randomized, double-blind, controlled study conducted in Santiago, Chile, between 2016 and The study aimed to evaluate growth and body composition changes between birth and two years of age in a large sample of children who were randomized to receive either infant formula with or without added MFGM (milk fat globule membrane) through 12 months of age or received human milk as part of the reference group. In a subsample of 160 children, neurodevelopmental were assessed at 6 months and 24 months.
Detailed description
To test our hypothesis, this study proposes to investigate our conceptual model's direct and indirect associations using a combination of low-field MRI, electrophysiology, and psychometric assessments of executive functioning and general cognitive development, expecting to re-enroll approx 100 participants. These children will undergo ERPs, low-field MRI and neurocognitive testing to evaluate brain structure, function, and cognitive development.
The Go/No-Go task assesses inhibitory control, one of the most important executive function. Its development has been studied electrophysiologically using event-related potentials (ERPs), in tasks that require active inhibition when there is a previously learned or prepotent response. The main relevant ERP components are the N2 and P300. The N2, an early negative deflection, has been interpreted to reflect attention, the P300, a later positive wave, is thought to reflect resource allocation. The P300 is typically greater in the inhibitory than in the prepotent response components of tasks such as the Go/No-Go task. Behavioral responses such as accuracy and reaction time have also been studied as measures of development (2). Using the collected data, inhibitory control, as one of the earliest executive functions to begin developing, will be studied.
The data acquired with the Low-field MRI quantify and compare brain structure and myelination patterns (derived from MRI) across the feeding groups in specific white matter pathways and brain regions involved in executive function (EF) and throughout the brain generally. MRI comparisons and comparisons will be complemented by comparisons of ERP measures collected during an inhibition task, which assesses functional development and processing speed.In addition to these group-wise comparisons,it will be explored the direct and indirect infant feeding -> brain structure and function -> executive function and cognitive performance associations using a series of ANCOVA and general linear modeling methods.
- PRIMARY OBJECTIVE AND OUTCOME MEASUREMENTS:
The primary objective of this study is to determine whether additional intake of bMFGM during infancy (0-12 months of age) improves brain structure, function, and cognitive performance (specifically EF) at early school age (8-10 years of age).
The following measures will be collected, and EF domains assessed and comparisons made.
Brain Structure and Myelin Imaging. Low-Field MRI will be used to assess general brain growth and morphometry (total brain volume, whole-brain white and gray matter volume, and cortical and sub-cortical structure volumes) as well as myelination using myelin-sensitive MRI. Differences across all of these measures between the infant feeding groups (standard formula, added bMFGM, and breastfeeding reference) will be part of exploratory analysis. To examine specific hypothesized brain regions involved in EF, including prefrontal cortex, hippocampus, amygdala, thalamus, motor and somatosensory cortices, and auditory cortex will be studied. Connecting white matter regions, including corpus callosum, cingulum, superior longitudinal fasciculus, and anterior thalamic radiations will be compared as they are an indirect index of myelination grade.
Mean myelin measures will be calculated for each white matter pathway and compared across the three feeding groups using an ANCOVA and post hoc Tukey test to identify significant differences.
ERPs and Electrophysiology. ERPs will be recorded from 128 scalp sites using a recording system with a geodesic sensor net (Electric Geodesic, Inc., Eugene, Oregon). The vertex was used as the on-line reference electrode. The signal was sampled at 1000 Hz and bandpass filtered at 0.1 to 100 Hz. After recording, stimulus triggers were exported and analyzed using signal processing software (BESA Research 6.1 BESA® ,Germany). Signals were re-referenced off-line to an average (whole head) reference and bandpass filtered (0.1 to 10 Hz). The continuous EEG was segmented into epochs according to the three stimulus types: block 1 Go trials, block 2 Go trials, and block 2 No-Go trials with the segment length being the same as each onset-to-onset interval. Noisy segments of data with excessive electromyographic signal (EMG) were rejected by visual inspection, and noisy channels were identified and rejected using a 2.5% probability threshold and visual inspection. Each trial will last 1000ms and consist of 100ms of pre-stimulus presentation, 500ms of stimulus presentation, and 1000ms of stimulus recording. The intertrial interval was 500 to 700ms. For the ERP analysis, window time was selected to establish where to determine the components of interest, which were identified relative to the number of major positive and negative peaks following stimulus onset. All time window values were relative to stimulus onset, and the peak amplitudes were calculated relative to the baseline amplitude. Statistical analyses were conducted with SPSS software version 25.0.1 (SPSS Inc., Chicago, IL, USA). Behavioral measures were reaction time and accuracy. Electrophysiological measures were peak amplitude and latency for N2 and amplitude for P300. Covariates that indicated group differences were considered in subsequent analyses as potential confounders.
Age-appropriate EF Psychometric Assessments will be used to evaluate executive functions. The EFECO assessment that are the abbreviation Evaluation of executive function throughout conductual observation. The questionnaire will be filled by the adult in charge of the participant.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| FM EM | – | Diagnostic Test: ImagingDuring the first year of life the participants received 1. regular formula milk 2. enriched with Milk Fat Membrane Globule formula |
Who may qualify
- Ages
- 10 to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- Study population was selected from the neighborhoods close to the installation of research institute. The area corresponds to the southeast of Santiago, Chile
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ImagingAlso: Event related potential testThe participants will be assessed with a brain MRI and will performed a neurophysiological test to evaluate executive functions | Diagnostic test | FM EM |
Primary outcome
To determine if intake of bMFGM during the first year improves brain structure at 9 ys.
Time frame: MRI assessment will be performed at 9 years old in a session of 45 minutes
Low-Field MRI will be used to assess general brain growth and morphometry (total brain volume, whole-brain white and gray matter volume, and cortical and sub-cortical structure volumes) as well as myelination using myelin-sensitive MRI. For specific analysis will examine brain regions involved in EF, including prefrontal cortex, hippocampus, amygdala, thalamus, motor and somatosensory cortices, and auditory cortex ; and connecting white matter regions, including corpus callosum, cingulum, superior longitudinal fasciculus, and anterior thalamic radiations .The results will be expressed by mean volumetric measures calculate from the MRI data using validated FreeSurfer software and compared across the groups using an ANCOVA, controlling for variables of interest. Mean myelin measures will be calculated for each white matter pathway and to identify significant differences (express by grade of myelination)
To determine if intake of bMFGM during the first year improves EF measures by ERPs at 9ys.
Time frame: ERPs assessment will be performed at 9 years old in a a second session of 90 minutes .
. To assess EF the Go No Go task will be performed with ERPs. The participant will ask to press a button when any letter appears (Go stimulus) except when the letter will be X (No Go stimulus). There will be 2 blocks: Block 1(40 trials) of Go stimulus and Block 2 (200 trials) of randomized Go and No Go stimuli. Neurophysiological responses will be recorded from 128 scalp sites using a recording system with a geodesic sensor net .For the ERP analysis, the major positive and negative peaks following stimulus onset will be identified. Statistical analyses were conducted with SPSS software version 25.0.1. Behavioral measures will be reaction time (ms) and accuracy (%). Electrophysiological results will be the peak amplitude (mµ) and latency (ms) for the waves N2 and P300.
To determine if intake of bMFGM during the first year improves EF measures by questionnaire EFECO.
Time frame: EFECO will be answered by the adult that ERPs assessment will be performed at 9 years old in a a second session of 90 minutes .
The questionnaire EFECO evaluates executive functions throughout conductual observation. The scale has 67 questions which measure seven different executive functions: cognitive flexibility, emotional control, planification capacity, organization, initiative and working memory. The quantification of each item goes from 0 to 3 according with one of these responses: Never, sometime, frequently, and very frequently. The higher score corresponds to a better EF. The questionnaire will be filled by the adult accompanying the participant during the ERP measurement and confirm that lives with the participant.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2025.
- Individual participant dataSharing planned: Yes. The data published in an article could be share with other researchers
Related trials for Child Development
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Not yet recruiting
Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss
Hearing Loss, Bilateral
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patricio Peirano, MD study director
University of Chile
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Child Development, run by Corporación de Apoyo de la Investigación Científica en Nutrición at 1 site in Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine if intake of bMFGM during the first year improves brain structure at 9 ys. (time frame: MRI assessment will be performed at 9 years old in a session of 45 minutes). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2025.